Profusa Inc PFSA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Profusa Receives ISO 13485:2016 Certificate from GMED
-
Profusa Announces Significant Progress Towards Lumee® Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October
-
Profusa, Inc. Receives Nasdaq Compliance Determination
-
Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement
-
Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company
-
Profusa Announces 1-for-4 Reverse Stock Split
-
Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs
Trading Information
- Previous Close Price
- $0.77
- Day Range
- $0.71–0.78
- 52-Week Range
- $0.70–3,000.00
- Bid/Ask
- $0.76 / $0.77
- Shares Outstanding
- 605,647.00
- Market Cap
- $466,893.27
- Volume/Avg
- 182,082 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.profusa.com
Valuation
|
Metric
|
PFSA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PFSA
Financial Strength
|
Metric
|
PFSA
|
|---|---|
Quick Ratio | 0.03 |
Current Ratio | 0.03 |
Interest Coverage | −183.42 |
Quick Ratio
PFSA
Profitability
|
Metric
|
PFSA
|
|---|---|
Return on Assets (Normalized) | −1,791.59% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
PFSA
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|@kY>qL | LOCK|HCy?& | $178B | |||
| Medtronic PLC
MDT
| LOCK|^g>T$F | LOCK|M$C>w | $121B | |||
| Stryker Corp
SYK
| LOCK|Q?$W^wbN | LOCK|%@^ | $117B | |||
| Boston Scientific Corp
BSX
| LOCK|Jln?G@ | LOCK|HFy>! | $61B | |||
| Edwards Lifesciences Corp
EW
| LOCK|&Q@kKLn | LOCK|kl^s^ | $53B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|khL%>W# | LOCK|dkg | $34B | |||
| DexCom Inc
DXCM
| LOCK|D&vcXpG@ | LOCK|!h>h | $30B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|&g | LOCK|Cb | $26B | |||
| Steris PLC
STE
| LOCK|^^Y^bL | LOCK|vF%@ | $22B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|&$RfDf@> | LOCK|>^ | $18B |
United States